Myeloid bodies in the renal tubules of humans

Relationship to gentamicin therapy

Donald Houghton, M. V. Campbell-Boswell, W. M. Bennett, G. A. Porter, R. E. Brooks

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Ultrastructural changes in renal proximal tubule lysosomes, including the formation of myeloid bodies occur reliably with gentamicin administration in experimental animals. The present study reviewed the electron microscopic tubular morphology of renal biopsies and nephrectomies performed in our institution over a 2-year period. The frequency of myeloid bodies and their relation to drug therapy and selected clinical features were determined. Myeloid bodies were found in the proximal tubules of 19 of 109 cases that were judged adequate for study. On review of the drug histories of these 19 patients, 15 had received gentamicin within 6 weeks of biopsy or nephrectomy. None of the 90 patients without myeloid bodies had received the drug within 6 weeks of tissue examination. Of 4 patients with myeloid bodies who had not received gentamicin, 1 had received chloroquin and 3 had received drugs with no known or suspected capacity to induce myeloid bodies. The presence of myeloid bodies in proximal tubules did not appear to be related to the total dose of gentamicin, duration of therapy, or serum drug concentration. Clinical evidence of gentamicin nephrotoxicity was present in only 1 case.

Original languageEnglish (US)
Pages (from-to)140-145
Number of pages6
JournalClinical Nephrology
Volume10
Issue number4
StatePublished - 1978

Fingerprint

Gentamicins
Kidney
Nephrectomy
Pharmaceutical Preparations
Biopsy
Therapeutics
Proximal Kidney Tubule
Chloroquine
Lysosomes
Electrons
Drug Therapy
Serum

ASJC Scopus subject areas

  • Nephrology

Cite this

Houghton, D., Campbell-Boswell, M. V., Bennett, W. M., Porter, G. A., & Brooks, R. E. (1978). Myeloid bodies in the renal tubules of humans: Relationship to gentamicin therapy. Clinical Nephrology, 10(4), 140-145.

Myeloid bodies in the renal tubules of humans : Relationship to gentamicin therapy. / Houghton, Donald; Campbell-Boswell, M. V.; Bennett, W. M.; Porter, G. A.; Brooks, R. E.

In: Clinical Nephrology, Vol. 10, No. 4, 1978, p. 140-145.

Research output: Contribution to journalArticle

Houghton, D, Campbell-Boswell, MV, Bennett, WM, Porter, GA & Brooks, RE 1978, 'Myeloid bodies in the renal tubules of humans: Relationship to gentamicin therapy', Clinical Nephrology, vol. 10, no. 4, pp. 140-145.
Houghton D, Campbell-Boswell MV, Bennett WM, Porter GA, Brooks RE. Myeloid bodies in the renal tubules of humans: Relationship to gentamicin therapy. Clinical Nephrology. 1978;10(4):140-145.
Houghton, Donald ; Campbell-Boswell, M. V. ; Bennett, W. M. ; Porter, G. A. ; Brooks, R. E. / Myeloid bodies in the renal tubules of humans : Relationship to gentamicin therapy. In: Clinical Nephrology. 1978 ; Vol. 10, No. 4. pp. 140-145.
@article{9815acc8ceea4a2f951098be8297c958,
title = "Myeloid bodies in the renal tubules of humans: Relationship to gentamicin therapy",
abstract = "Ultrastructural changes in renal proximal tubule lysosomes, including the formation of myeloid bodies occur reliably with gentamicin administration in experimental animals. The present study reviewed the electron microscopic tubular morphology of renal biopsies and nephrectomies performed in our institution over a 2-year period. The frequency of myeloid bodies and their relation to drug therapy and selected clinical features were determined. Myeloid bodies were found in the proximal tubules of 19 of 109 cases that were judged adequate for study. On review of the drug histories of these 19 patients, 15 had received gentamicin within 6 weeks of biopsy or nephrectomy. None of the 90 patients without myeloid bodies had received the drug within 6 weeks of tissue examination. Of 4 patients with myeloid bodies who had not received gentamicin, 1 had received chloroquin and 3 had received drugs with no known or suspected capacity to induce myeloid bodies. The presence of myeloid bodies in proximal tubules did not appear to be related to the total dose of gentamicin, duration of therapy, or serum drug concentration. Clinical evidence of gentamicin nephrotoxicity was present in only 1 case.",
author = "Donald Houghton and Campbell-Boswell, {M. V.} and Bennett, {W. M.} and Porter, {G. A.} and Brooks, {R. E.}",
year = "1978",
language = "English (US)",
volume = "10",
pages = "140--145",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "4",

}

TY - JOUR

T1 - Myeloid bodies in the renal tubules of humans

T2 - Relationship to gentamicin therapy

AU - Houghton, Donald

AU - Campbell-Boswell, M. V.

AU - Bennett, W. M.

AU - Porter, G. A.

AU - Brooks, R. E.

PY - 1978

Y1 - 1978

N2 - Ultrastructural changes in renal proximal tubule lysosomes, including the formation of myeloid bodies occur reliably with gentamicin administration in experimental animals. The present study reviewed the electron microscopic tubular morphology of renal biopsies and nephrectomies performed in our institution over a 2-year period. The frequency of myeloid bodies and their relation to drug therapy and selected clinical features were determined. Myeloid bodies were found in the proximal tubules of 19 of 109 cases that were judged adequate for study. On review of the drug histories of these 19 patients, 15 had received gentamicin within 6 weeks of biopsy or nephrectomy. None of the 90 patients without myeloid bodies had received the drug within 6 weeks of tissue examination. Of 4 patients with myeloid bodies who had not received gentamicin, 1 had received chloroquin and 3 had received drugs with no known or suspected capacity to induce myeloid bodies. The presence of myeloid bodies in proximal tubules did not appear to be related to the total dose of gentamicin, duration of therapy, or serum drug concentration. Clinical evidence of gentamicin nephrotoxicity was present in only 1 case.

AB - Ultrastructural changes in renal proximal tubule lysosomes, including the formation of myeloid bodies occur reliably with gentamicin administration in experimental animals. The present study reviewed the electron microscopic tubular morphology of renal biopsies and nephrectomies performed in our institution over a 2-year period. The frequency of myeloid bodies and their relation to drug therapy and selected clinical features were determined. Myeloid bodies were found in the proximal tubules of 19 of 109 cases that were judged adequate for study. On review of the drug histories of these 19 patients, 15 had received gentamicin within 6 weeks of biopsy or nephrectomy. None of the 90 patients without myeloid bodies had received the drug within 6 weeks of tissue examination. Of 4 patients with myeloid bodies who had not received gentamicin, 1 had received chloroquin and 3 had received drugs with no known or suspected capacity to induce myeloid bodies. The presence of myeloid bodies in proximal tubules did not appear to be related to the total dose of gentamicin, duration of therapy, or serum drug concentration. Clinical evidence of gentamicin nephrotoxicity was present in only 1 case.

UR - http://www.scopus.com/inward/record.url?scp=0018080546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018080546&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 140

EP - 145

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 4

ER -